Aardvark Therapeutics, Inc. (AARD)
NASDAQ · Healthcare
Aardvark Therapeutics, Inc. Revenue 2024–2025
Aardvark Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2024 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Aardvark Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 0.
- Aardvark Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 2.8 M.
- Aardvark Therapeutics, Inc. annual revenue for 2025 was 0, a 100.00% decrease from 2024.
- Aardvark Therapeutics, Inc. annual revenue for 2024 was 2.4 M.
Revenue
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Aardvark Therapeutics, Inc. (AARD) — Frequently Asked Questions
Aardvark Therapeutics, Inc. (AARD) is a publicly traded US company. It has a market capitalization of $68M. Explore AARD's stock price, financial statements, earnings history, margins and key ratios below.
What is Aardvark Therapeutics, Inc.'s market cap?
Aardvark Therapeutics, Inc. (AARD) has a market capitalization of $68M.
What is the AARD stock price?
AARD trades at $3.48 (-2.79% on the day).
Is AARD profitable?
In fiscal 2025, Aardvark Therapeutics, Inc. reported net income of -$58M.